



Office of Communications • 401 East Pratt Street • Baltimore, Maryland 21202 Contact: Karen Glenn Hood • 410.767.6318 • kglenn@choosemaryland.org

EMERGENT BIOSOLUTIONS TAPS EAST BALTIMORE FOR BIOPROCESSING CENTER, PLANS TO CREATE 125 NEW JOBS

BALTIMORE, MD (**November 13, 2009**) – Governor Martin O'Malley and MdBio Foundation Inc. today announced that Emergent BioSolutions, a Maryland-based biopharmaceutical company, will open a biotechnology manufacturing facility in East Baltimore and create up to 125 jobs over the next five years. The company, which focuses on the development, manufacture and commercialization of vaccines and therapeutics, has purchased MdBio Foundation's 55,000 square-foot BioProcessing Center at 5901 E. Lombard St. to enhance its manufacturing infrastructure. Emergent BioSolutions is the manufacturer of BioThrax[®], the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax disease. Emergent's development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.

"Maryland is continuing to strengthen its place as a global hub for an emerging biotechnology industry by helping to grow industry leaders like Emergent BioSolutions," said Governor O'Malley. "This transaction will capitalize on Maryland's unique assets, location, and world class workforce, enabling additional economic activity and creating high paying, highly skilled jobs throughout our State."

"The acquisition of the Baltimore facility reflects our commitment to both continually creating jobs and investing additional capital in the State of Maryland, where Emergent headquarters and one of its product development sites are located," said Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions. "We extend our sincere appreciation to the state and local governments for their ongoing support of our efforts to develop our local manufacturing capabilities and look forward to growing Emergent's presence in the state."

As part of the project, the Maryland Department of Business and Economic Development will offer Emergent a \$50,000 grant through the Brownfields Revitalization Incentive Program to assist with the costs of assessment studies for the East Baltimore site. In addition, the company is eligible for Job Creation Tax Credits, the One Maryland Tax Credit and benefits from locating in an Enterprise Zone.

"Emergent's decision to expand in Maryland underscores not only our rich research and development environment, but also our mission to support the complete product development life cycle that includes bio manufacturing," said Maryland Department of Business and Economic Development Secretary Christian S. Johansson. "The Department, through the Maryland Biotechnology Center, was pleased to work with MdBio Foundation and the Baltimore Development Corp. to bring this project to fruition."

Baltimore City, which owns the land on which the BioProcessing Center sits, offered a \$250,000 credit on the purchase price of the land as an incentive for job creation.

Mayor Sheila Dixon, commenting on the announcement, said, "The City of Baltimore is excited about welcoming Emergent BioSolutions to the Baltimore biotech community. With great research institutions such as Johns Hopkins and the University of Maryland as potential partners in the area, we know that Emergent will be a wonderful contributor in the future."

"Though no longer owner of the center, MdBio will continue its important mission to promote and support the bioscience community throughout the state," said J.J. Finkelstein, chair of MdBio Foundation, Inc. and president and chief executive officer of RegeneRx Biopharmaceuticals, Inc. "The Foundation's scholarship and educational programs, as well as its business advisory services, have been exceptionally well received by the bioscience community. We look forward to continuing these innovative programs and help make Maryland one of the premiere bioscience communities in the world"

ABOUT DBED:

The Maryland Department of Business and Economic Development stimulates private investment and creates jobs by attracting new businesses, encouraging the expansion and retention of existing companies, and providing workforce training and financial assistance to Maryland companies. The Department promotes the State's many economic advantages and markets local products and services at home and abroad to spur economic development and international investment, trade and tourism. Because they are major economic generators, the Department also supports the Arts, film production, sports and other special events. For more information, visit www.choosemaryland.org.

ABOUT MDBIO FOUNDATION, INC.

The MdBio Foundation, Inc. is a charitable and educational organization whose mission is to provide and support the State of Maryland's bioscience community through bioscience awareness, education and workforce development programs including scholarships, post-doctoral conference and career expos, BioGENEius science competition and summer science camps. Since 2003, MdBio has operated the MdBioLab, an educational and well-known mobile bioscience laboratory that visits high schools throughout Maryland to educate youth on biosciences. Over the past six years, MdBioLab has held more than 2,800 classes with 55,000 students and 1,500 teachers. MdBio Foundation became an affiliate of the Tech Council of Maryland in 2006.

ABOUT EMERGENT BIOSOLUTIONS INC.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax disease. Emergent's development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.